SCIENTURE to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with

to commercially launch REZENOPY , a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY

FL, March 06, 2025 (GLOBE NEWSWIRE) - SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical

operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market,

and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture,

LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary

of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY

(naloxone HCl) Nasal Spray 10mg, an opioid antagonist that was approved by the FDA on April 19, 2024.

the terms of the collaboration, Kindeva will manufacture and commercially supply REZENOPY (naloxone HCl) Nasal Spray

10mg. Scienture will own the new drug application (NDA) for REZENOPY in its name and be responsible for the sales, marketing

and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.

is the most potent (highest strength) version of naloxone HCl available in the market. The product leverages the proven use of

the active ingredient and form factor, with increased effectiveness against potent opioids.

addition of REZENOPY to Scienture's product portfolio aligns with Scienture's mission to provide innovative

treatment solutions across therapeutic areas and expand access to patients. This product collaboration represents a strategic step in

advancing public health initiatives and ensuring that life-saving interventions are readily available to those at risk of opioid overdose.

As opioid-related fatalities continue to rise, Scienture is dedicated to collaborating with healthcare professionals, policymakers, and

advocacy groups to enhance awareness, education, and distribution efforts.

delivery of Naloxone HCl has been widely recognized for its efficacy, ease of use, and accessibility, making it an essential tool for

first responders, healthcare providers, and community programs. IQVIA data (MAT December 2024) indicates a total annual sales of $189

million, unit volume of $10.0 million (eaches) for Naloxone in the US market.

are proud to take this significant step in strengthening our commitment to combating the opioid epidemic," said Narasimhan Mani,

Ph.D., MBA, President of Scienture, LLC. "Through this collaboration with a well established and strong partner like Kindeva, we

now offer REZENOPY , a higher dose naloxone HCl option for communities, reinforcing our mission to deliver impactful healthcare

collaboration is not just about expanding our portfolio; it's about making a real difference in the fight against opioid addiction,"

added Shankar Hariharan, Ph.D., CEO of Scienture, LLC. "By working alongside public health agencies and community organizations,

we will drive meaningful change and save lives."

part of our commitment to fast-tracking healthier tomorrows, we are thrilled to be joining forces with Scienture to bring this life-saving

device to market," remarked Milton Boyer, CEO of Kindeva. "Our nasal drug delivery team has created a nasal spray that is

quick and simple to administer, and which has the potential to prevent unnecessary overdoses across the United States. We are dedicated

to ensuring this device reaches the people that need it most as quickly as possible and prevent more opioid related fatalities."

(naloxone HCl) Nasal Spray 10mg, is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose,

as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. It is intended for immediate administration

as emergency therapy in settings where opioids may be present.

nasal spray is for intranasal use only and is supplied as a carton containing two (2) blister packages each with a single spray

more detailed information, please refer to the full prescribing information provided by the FDA.

Scienture Holdings, Inc.

HOLDINGS, INC. (NASDAQ: "SCNX"), through its wholly owned subsidiaries, Scienture, LLC and Integra Pharma Solutions, LLC,

is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering

novel specialty products to satisfy unmet market needs. Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells

brand, generic and non-drug products to healthcare markets including government organizations, hospitals, clinics and independent pharmacies

nationwide. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals

who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare

systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and

channels. For more information please visit www.scienture.com.

Kindeva Drug Delivery L.P.

Drug Delivery is a leading global powerhouse CDMO for sterile injectable, pulmonary, nasal, transdermal, and intradermal finished dose.

We are committed to manufacturing more tomorrows for our customers, colleagues, and patients around the world. We deliver unrivaled expertise

across development, manufacturing, and comprehensive analytical services for a broad range of drug-delivery formats. Through strategic

investments in cutting-edge technology, we proactively tackle critical industry challenges, including expanding aseptic injectable fill-finish

capabilities and leading the way in green propellant initiatives. Combining forces with a diverse global client base, Kindeva operates

state-of-the-art manufacturing, research, and development facilities across the U.S. and U.K. For more information please visit www.kindevadd.com

Statements Regarding Forward-Looking Statements

press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities

laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical

are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange

Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking

statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry,

our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management

team's expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch and

the success those products may have in the marketplace. In addition, any statements that refer to projections, forecasts or other characterizations

of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify

forward-looking statements by the following words: "anticipate," "believe," "continue," "could,"

"estimate," "expect," "intend," "may," "ongoing," "plan," "potential,"

"predict," "project," "should," or the negative of these terms or other similar expressions, but

the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number

of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different

from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking

statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed,

and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests

under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims

relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal

proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks

detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking

statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided

6308 Benjamin Rd, Suite 708

Tampa, Florida 33634

Phone: (866) 468-6535

Email: IR@Scienture.com